Pricing Market Access Model Components, Stakeholders, & Functionality Assessment
Global Pharmaceutical Company
Client Problem
To understand what PMA (Pricing Market Access) model the competitor would develop for the introduction of their ultra-rare disease agent, more specifically seeking to understand functionality of a novel access model and the perceptions amongst payers as well as implications for patients and sustainability
EmPartners' Approach
We went to Washington DC to meet with two congress representatives to understand future pricing and reimbursement plans and expectations, as well as communicated with ICER representatives to get a deep understanding of the value assessment
We spoke to the competitor's executive leadership team to understand their respective market access and introduction plans, and met with industry leaders to understand and map out the insurance/payer translation of this concept
Client Impact
The client received
the exact pricing, PMA model of the ultra rare drug, months prior to the actual launch and was able to define and implement a competitive strategic response
